Výsledky vyhledávání - "Inflammation/*drug therapy"

nanoGold and µGold inhibit autoimmune inflammation: a review

Publikováno v: Danscher, G & Rasmussen, S 2023, ' nanoGold and µGold inhibit autoimmune inflammation : a review ', Histochemistry and cell biology, vol. 159, no. 3, pp. 225-232 . https://doi.org/10.1007/s00418-023-02182-9
Danscher, G & Rasmussen, S 2023, ' nanoGold and µGold inhibit autoimmune inflammation : a review ', Histochemistry and Cell Biology, vol. 159, no. 3, pp. 225-232 . https://doi.org/10.1007/s00418-023-02182-9

The newest data on metallic gold have placed the noble metal central in the fight for the safe treatment of autoimmune inflammation. There are two different ways to use gold for the treatment of inflammation: gold microparticles > 20 µm and gold nan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c92e91fcdf420a111b7ed25a302918c
https://doi.org/10.1007/s00418-023-02182-9

Zobrazit plný text záznamu

Plný text ve formátu HTML

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease

Autor: Jakob A. Østergaard, Jay C. Jha, Arpeeta Sharma, Aozhi Dai, Judy S.Y. Choi, Judy B. de Haan, Mark E. Cooper, Karin Jandeleit-Dahm

Publikováno v: Østergaard, J A, Jha, J C, Sharma, A, Dai, A, Choi, J S Y, De Haan, J B, Cooper, M E & Jandeleit-Dah, K 2022, ' Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease ', Clinical Science, vol. 136, no. 2, pp. 167-180 . https://doi.org/10.1042/CS20210865
Clinical Science (London, England : 1979)

Activation of nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome has been reported in diabetic complications including diabetic kidney disease (DKD). However, it remains unknown if NLRP3 inhibition

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb74c1c6696820a6519eb2f38a2726e
https://doi.org/10.1042/cs20210865

Zobrazit plný text záznamu

Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases

Autor: Tadashi Matsuda, Ryuta Muromoto, Kenji Oritani, Kazuya Shimoda

Publikováno v: Biological and Pharmaceutical Bulletin. 44:1585-1592

Tyrosine kinase 2 (Tyk2) is a member of the Janus family of protein tyrosine kinases (Jaks). Tyk2 associates with interferon (IFN)-α, IFN-β, interleukin (IL)-6, IL-10, IL-12, and IL-23 receptors and mediates their downstream signaling pathways. Bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f8ce2048df228ae684a00291d4a2e9
https://doi.org/10.1248/bpb.b21-00609

Zobrazit plný text záznamu

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

Autor: Speetjens, F.M., Welters, M.J.P., Slingerland, M., Poelgeest, M.I.E. van, Steenwijk, P.J.D. van, Roozen, I., Boekestijn, S., Loof, N.M., Zom, G.G., Valentijn, A.R.P.M., Krebber, W.J., Meeuwenoord, N.J., Janssen, C.A.H., Melief, C.J.M., Marel, G.A. van der, Filippov, D.V., Burg, S.H. van der, Gelderblom, H., Ossendorp, F.

Publikováno v: Journal for ImmunoTherapy of Cancer, 10(10):e005016. BMJ PUBLISHING GROUP
Journal for ImmunoTherapy of Cancer, 10(10). BMJ PUBLISHING GROUP
Journal for ImmunoTherapy of Cancer, 10(10):e005016. BioMed Central Ltd

BackgroundAmplivant is a molecularly optimized Toll-like receptor 2 ligand that can be covalently conjugated to tumor peptide antigens. In preclinical models, amplivant-adjuvanted synthetic long peptides (SLPs) strongly enhanced antigen presentation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d93023b7ce9dacaa1cc2e7642a8718
http://hdl.handle.net/1887/3502420

Zobrazit plný text záznamu

Preterm Birth Therapies to Target Inflammation

Autor: Pavlidis, Ioannis, Stock, Sarah J E

Publikováno v: Pavlidis, I & Stock, S J E 2022, ' Preterm birth therapies to target inflammation ', Journal of Clinical Pharmacology, vol. 62 Suppl 1, pp. S79-S93 . https://doi.org/10.1002/jcph.2107

Preterm birth (PTB; defined as delivery before 37 weeks of pregnancy) is the leading cause of morbidity and mortality in infants and children aged5 years, conferring potentially devastating short- and long-term complications. Despite extensive resear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c0e0c7968b3fc73cca5163b7e75e7b
https://doi.org/10.1002/jcph.2107

Zobrazit plný text záznamu

Nanoencapsulation of Gla-Rich Protein (GRP) as a Novel Approach to Target Inflammation

Autor: Carla S. B. Viegas, Nuna Araújo, Joana Carreira, Jorge F. Pontes, Anjos L. Macedo, Maurícia Vinhas, Ana S. Moreira, Tiago Q. Faria, Ana Grenha, António A. de Matos, Leon Schurgers, Cees Vermeer, Dina C. Simes

Publikováno v: International Journal of Molecular Sciences; Volume 23; Issue 9; Pages: 4813
International journal of molecular sciences, 23(9):4813. Multidisciplinary Digital Publishing Institute (MDPI)

Funding: This research was funded by Portuguese National Funds from FCT—Foundation for Science and Technology, through the transitional provision DL57/2016/CP1361/CT0006, projects EXPL/BTM-TEC/0990/2021, UIDB/04326/2020, UIDP/04326/2020 and LA/P/01

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f8f3614d6956a74dd2d767e462a5216
https://hdl.handle.net/10362/143302

Zobrazit plný text záznamu

Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis

Autor: James M Gwinnutt, Sam Norton, Kimme L Hyrich, Mark Lunt, Bernard Combe, Nathalie Rincheval, Adeline Ruyssen-Witrand, Bruno Fautrel, Daniel F McWilliams, David A Walsh, Elena Nikiphorou, Patrick D W Kiely, Adam Young, Jacqueline R Chipping, Alex MacGregor, Suzanne M M Verstappen

Publikováno v: Gwinnutt, J M, Norton, S, Hyrich, K L, Lunt, M, Combe, B, Rincheval, N, Ruyssen-Witrand, A, Fautrel, B, McWilliams, D F, Walsh, D A, Nikiphorou, E, Kiely, P, Young, A, Chipping, J R, MacGregor, A & Verstappen, S M M 2022, ' Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis ', Rheumatology (Oxford, England), vol. 61, no. 12, pp. 4687-4701 . https://doi.org/10.1093/rheumatology/keac137
Rheumatology
Rheumatology, 2022, 61 (12), pp.4687-4701. ⟨10.1093/rheumatology/keac137⟩
Gwinnutt, J M, Norton, S, Hyrich, K L, Lunt, M, Combe, B, Rincheval, N, Ruyssen-Witrand, A, Fautrel, B, McWilliams, D F, Walsh, D A, Nikiphorou, E, Kiely, P, Young, A, Chipping, J R, MacGregor, A & Verstappen, S M M 2022, ' Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis ', Rheumatology, vol. 61, no. 12, pp. 4687-4701 . https://doi.org/10.1093/rheumatology/keac137

Objectives To identify groups of people with RA with different disability trajectories over 10 years, despite comparable levels of inflammation. Methods Data for this analysis came from three European prospective cohort studies of people with RA [Nor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586791e75497ab231011871e0dd010c9

Zobrazit plný text záznamu

Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness

Autor: Abi G. Yates, Caroline M. Weglinski, Yuxin Ying, Isobel K. Dunstan, Tatyana Strekalova, Daniel C. Anthony

Publikováno v: Journal of Neuroinflammation, Vol 19, Iss 1, Pp 1-16 (2022)
Yates, A G, Weglinski, C M, Ying, Y, Dunstan, I K, Strekalova, T & Anthony, D C 2022, ' Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness ', Journal of Neuroinflammation, vol. 19, 8 . https://doi.org/10.1186/s12974-021-02357-y
Journal of Neuroinflammation

Background The serine protease inhibitor nafamostat has been proposed as a treatment for COVID-19, by inhibiting TMPRSS2-mediated viral cell entry. Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff4d7186f1eedb509337a7370816993
https://doi.org/10.1186/s12974-021-02357-y

Zobrazit plný text záznamu

The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: immune homeostatic mechanisms in the artery wall

Autor: Daniel F. J. Ketelhuth

Publikováno v: Ketelhuth, D F J 2019, ' The immunometabolic role of indoleamine 2 3-dioxygenase in atherosclerotic cardiovascular disease : immune homeostatic mechanisms in the artery wall ', Cardiovascular Research, vol. 115, no. 9, pp. 1408-1415 . https://doi.org/10.1093/cvr/cvz067

Coronary heart disease and stroke, the two most common cardiovascular diseases worldwide, are triggered by complications of atherosclerosis. Atherosclerotic plaques are initiated by a maladaptive immune response triggered by accumulation of lipids in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::754e76d35f41858a7875f9f81b073d6d
https://doi.org/10.1093/cvr/cvz067

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání